Najat Khan
CIK: 0002020969
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
RECURSION PHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- Sep 8, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct22.4K shares at avg. $3.52$79K - Aug 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct80.5K shares at avg. $3.16$254K - Jun 5, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct23.6K shares at avg. $3.58$84K - May 15, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct62.7K shares at avg. $3.04$191K - Mar 9, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct28.3K shares at avg. $3.35$95K - Feb 17, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct14.3K shares at avg. $3.49$50K - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct1.7M shares- - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct30.3K shares- - Feb 6, 2026RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct10.4K shares at avg. $3.98$41K - Dec 22, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct124.4K shares at avg. $4.41$549K - Nov 17, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct17.6K shares at avg. $4.14$73K - Nov 5, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct84.9K shares- - Aug 18, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Sale(S)Direct36.6K shares at avg. $5.52$202K - Aug 15, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct3.8K shares at avg. $5.64$21K - May 15, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct3.8K shares at avg. $4.25$16K - Feb 3, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct210.1K shares- - Feb 3, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Award(A)Direct8K shares- - Feb 3, 2025RXRX
RECURSION PHARMACEUTICALS, INC.
Tax Payment(F)Direct2.8K shares at avg. $7.25$20K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 8, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 22,408 | $3.52 | $78,822 | Direct |
| Aug 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 80,498 | $3.16 | $254,374 | Direct |
| Jun 5, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 23,588 | $3.58 | $84,459 | Direct |
| May 15, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 62,701 | $3.04 | $190,611 | Direct |
| Mar 9, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 28,298 | $3.35 | $94,660 | Direct |
| Feb 17, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 14,280 | $3.49 | $49,837 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 1,673,546 | - | $0 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 30,346 | - | $0 | Direct |
| Feb 6, 2026 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 10,364 | $3.98 | $41,249 | Direct |
| Dec 22, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 124,403 | $4.41 | $548,592 | Direct |
| Nov 17, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 17,584 | $4.14 | $72,798 | Direct |
| Nov 5, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 84,925 | - | - | Direct |
| Aug 18, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Sale(S) | 36,599 | $5.52 | $202,173 | Direct |
| Aug 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 3,789 | $5.64 | $21,370 | Direct |
| May 15, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 3,796 | $4.25 | $16,133 | Direct |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 210,113 | - | - | Direct |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Award(A) | 8,049 | - | - | Direct |
| Feb 3, 2025 | RXRX RECURSION PHARMACEUTICALS, INC. | Tax Payment(F) | 2,753 | $7.25 | $19,959 | Direct |
1-18 of 18 transactions
About Khan Najat
Khan Najat (SEC CIK 0002020969) files insider reports with the SEC as CEO and President of RECURSION PHARMACEUTICALS, INC. (RXRX).
Signal8 holds 13 ownership filings by Khan Najat, all Form 4s, filed between Feb 5, 2025 and Sep 10, 2026. Those filings report 18 transactions, from Feb 3, 2025 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Khan Najat's filings is in SALT LAKE CITY, UT.
Recent filings by Khan Najat
- Sep 8, 2026: Open-market sale of RXRX shares (Form 4, code S).
- Aug 17, 2026: Tax withholding of RXRX shares (Form 4, code F).
- Jun 5, 2026: Open-market sale of RXRX shares (Form 4, code S).
- May 15, 2026: Tax withholding of RXRX shares (Form 4, code F).
- Mar 9, 2026: Open-market sale of RXRX shares (Form 4, code S).
Other insiders filing for RECURSION PHARMACEUTICALS, INC. (RXRX)
- Borgeson Blake, Director
- HERSHBERG ROBERT, Director
- Dar Zavain, Director
- Li Dean Y, Director
- Taylor Ben R, Chief Financial Officer
- Hallett David, Chief Scientific Officer